Navigation Links
TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting
Date:12/11/2011

MALVERN, Pa., Dec. 11, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego. The study, conducted at The University of Texas M. D. Anderson Cancer Center, demonstrated that TL32711 induces apoptosis in acute myeloid leukemia (AML) cells, including AML stem/progenitor cells, alone and in combination with chemotherapy.

"TL32711 demonstrated single agent activity against blasts obtained from newly diagnosed AML patients and in CD34+38- stem/progenitor cells isolated from blasts of these patients, with no toxicity in CD34+ cells from normal bone marrows at doses effective against AML cells," said Michael Andreeff, M.D., Ph.D. Professor of Medicine and Chief, Molecular Hematology & Therapy, Departments of Leukemia and Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center. "When combined with various nucleoside analogues clinically used in AML therapy such as Ara-C, clofarabine, and demethylating agents decitabine and 5-azacytidine, TL32711 synergistically enhanced apoptotic cell death in AML cells and AML stem/progenitor cells."

TetraLogic recently announced the initiation of a Phase 1/2 clinical trial of TL32711 in elderly patients with AML. The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors. In the clinical studies to date, TL32711 has been well tolerated and exhibited rapid suppression of IAPs and antitumor activity.

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.

Media Contact:         

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
tony.russo@russopartnersllc.com
andreas.marathis@russopartnersllc.com

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900


'/>"/>
SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
3. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
4. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 28, 2016 TapImmune,Inc. (TPIV), ... peptide and gene-based immunotherapeutics and vaccines for the treatment of ... at the 3rd Annual Growth Capital Expo to ... 2016 at Caesars Palace in Las Vegas, Nevada.  The ... May 4 th by Dr. John N. Bonfiglio ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... data for 2014. Each year, reproductive endocrinologists are required to report in ... main organization of professionals dedicated to the practice of assisted reproductive technologies in ...
(Date:4/29/2016)... Los Angeles, California (PRWEB) , ... April 29, 2016 , ... ... all across USA, 1Heart Caregiver Services continues its successful franchise development and expansion as ... Ferdie has an extensive managerial and administrative experience in his 32 years of working ...
(Date:4/28/2016)... Sacramento, Calif. (PRWEB) , ... April 28, 2016 ... ... subsidiary of the California Dental Association, today announced it has signed a letter ... Dentists Benefits Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... Leesburg, Va. (PRWEB) , ... April 28, 2016 ... ... Los Angeles was among the organization’s most successful events, attracting medical professionals from ... education courses, and stimulating networking events. , Opening Ceremonies Sunday, April 17 included ...
Breaking Medicine News(10 mins):